Metformin targets c-MYC oncogene to prevent prostate cancer

Carcinogenesis

Volumn 34, Issue 12, 2013, Pages 2823-2832

  Akinyeke, Tunde ^a   Matsumura, Satoko ^a   Wang, Xinying ^a   Wu, Yingjie ^b   Schalfer, Eric D ^c   Saxena, Anjana ^d   Yan, Wenbo ^e   Logan, Susan K ^c   Li, Xin ^a,c  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e New York She feels blessed to teach our future nurses and advocate for those in need   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; KI 67 ANTIGEN; METFORMIN; MYC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE AMPLIFICATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN STABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; METFORMIN; MICE; ONCOGENES; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANDROGEN;

EID: 84889001940     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt307     Document Type: Article

References (49)

1. Jemal,A. et al. (2010) Cancer statistics, 2010. CA Cancer J. Clin., 60, 277-300.
2. SEER (2012) SEER Stat Fact Sheets: Prostate. http://seer.cancer.gov/statfacts/html/prost.html. (31 January 2013, date last accessed).
3. Moser,L. et al. (2008) Hormone-refractory and metastatic prostate cancer-palliative radiotherapy. Front. Radiat. Ther. Oncol., 41, 117-125.
4. Bostwick,D.G. (1988) Premalignant lesions of the prostate. Semin. Diagn. Pathol., 5, 240-253.
5. Colanzi,P. et al. (1998) Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation. Adv. Clin. Path., 2, 271-284.
6. Shin,H.J. et al. (1995) Prostatic intraepithelial neoplasia: a potential precursor lesion of prostatic adenocarcinoma. Yonsei Med. J., 36, 215-231.
7. Bethel,C.R. et al. (2006) Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res., 66, 10683-10690.
8. Iwata,T. et al. (2010) MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One, 5, e9427.
9. Jenkins,R.B. et al. (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res., 57, 524-531.
10. Dang,C.V. et al. (2009) MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res., 15, 6479-6483.
11. Bova,G.S. et al. (1996) Review of allelic loss and gain in prostate cancer. World J. Urol., 14, 338-346.
12. Neel,B.G. et al. (1982) Molecular analysis of the c-myc locus in normal tissue and in avian leukosis virus-induced lymphomas. J. Virol., 44, 158-166.
13. Takahashi,E. et al. (1991) Mapping of the MYC gene to band 8q24.12-- q24.13 by R-banding and distal to fra(8)(q24.11), FRA8E, by fluorescence in situ hybridization. Cytogenet. Cell Genet., 57, 109-111.
14. Ellwood-Yen,K. et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell, 4, 223-238.
15. Koh,C.M. et al. (2010) MYC and prostate cancer. Genes Cancer, 1, 617-628.
16. Gurel,B. et al. (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol., 21, 1156-1167.
17. Shaw,R.J. et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-1646.
18. Nobes,J.P. et al. (2011) A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 109, 1495-1502.
19. Shaw,RJ. et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91-99.
20. Chaudhary,S.C. et al. (2012) Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem. Photobiol., 88, 1149-1156.
21. Shi,W.Y. et al. (2012) Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis., 3, e275.
22. Ben Sahra,I. et al. (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res., 71, 4366-4372.
23. Kickstein,E. et al. (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl Acad. Sci. USA, 107, 21830-21835.
24. Vazquez-Martin,A. et al. (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 8, 88-96.
25. Ben Sahra,I. et al. (2010) The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy, 6, 670-671
26. Ben Sahra,I. et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res., 70, 2465-2475.
27. Watson,P.A. et al. (2005) Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res., 65, 11565-11571.
28. Thalmann,G.N. et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54, 2577-2581.
29. Wu,H.C. et al. (1994) Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer, 57, 406-412.
30. Kaighn,M.E. et al. (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17, 16-23.
31. Horoszewicz,J.S. et al. (1980) The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 37, 115-132.
32. Li,X. et al. (2011) Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. J. Bone Miner. Res., 26, 125-134.
33. Azoulay,L. et al. (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Biomarkers Prev., 20, 337-344.
34. Clegg,N.J. et al. (2011) MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One, 6, e17449.
35. Sawyers,C.L. (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell, 4, 343-348.
36. Majumder,P.K. et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF- 1-dependent pathways. Nat. Med., 10, 594-601.
37. Ben Sahra,I. et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-3586.
38. Zhao,L. et al. (2011) Metformin induces G1 cell cycle arrest and inhibits cell proliferation in nasopharyngeal carcinoma cells. Anat. Rec. (Hoboken), 294, 1337-1343.
39. Huai,L. et al. (2012) Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway. Biochem. Biophys. Res. Commun., 422, 398-404.
40. Wang,X. et al. (2011) Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res., 71, 925-936.
41. Arnold,H.K. et al. (2009) The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J., 28, 500-512.
42. Blandino,G. et al. (2012) Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat. Commun., 3, 865.
43. Sikka,A. et al. (2012) Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle, 11, 1374-1382.
44. Kim,J.W. et al. (1998) Transforming growth factor-beta 1 induces apoptosis through down-regulation of c-myc gene and overexpression of p27Kip1 protein in cervical carcinoma. Gynecol. Oncol., 69, 230-236.
45. Gibson,A.W. et al. (1995) Apoptosis induced by c-myc overexpression is dependent on growth conditions. Exp. Cell Res., 218, 351-358.
46. Ni,M. et al. (2013) Amplitude modulation of androgen signaling by c-MYC. Genes Dev., 27, 734-748.
47. Mostaghel,E.A. et al. (2011) New hormonal therapies for castrationresistant prostate cancer. Endocrinol. Metab. Clin. North Am., 40, 625-642, x.
48. Colquhoun,A.J. et al. (2012) Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis., 15, 346-352.
49. Dang,C.V. (2012) MYC on the path to cancer. Cell, 149, 22-35.